As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

“The average woman gains about six to seven pounds during this menopausal transitional period,” says Daniel H. Bessesen, MD, ...

A study found that GLP-1 RA use is linked to risks for retained gastric contents during single endoscopic procedures but not ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Trinian Taylor, a 52-year-old car dealer, pushed his cart through the aisles of a supermarket as I pretended not to follow ...

The holidays are near, and so is the season of eating decadent meals – and sometimes, overeating. Overindulging on food is ...

The COVID pandemic set in motion trends with alcohol use that have persisted. Disruptions in work, school and lifestyle have ...

Dr. Church continues, “GLP-1s have the potential to be life-changing, but achieving lasting success requires a more well-rounded approach—one that supports nutrition, lifestyle, and daily habits.